H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biora Therapeutics (BIOR – Research Report) today and set a price target of $65.00. The company’s shares opened today at $3.63.
According to TipRanks, Pantginis is an analyst with an average return of -2.8% and a 36.27% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Panbela Therapeutics, Celldex, and Onconova Therapeutics.
Currently, the analyst consensus on Biora Therapeutics is a Moderate Buy with an average price target of $65.00.
See the top stocks recommended by analysts >>
BIOR market cap is currently $51.2M and has a P/E ratio of -0.77.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Progenity Inc is a biotechnology company. It is engaged in developing and commercializing molecular testing products. The company is translating innovation into precision medicine through diagnostic and therapeutic development platforms based on genomics, proteomics, and microbiomics. The firm generates its revenue from molecular laboratory tests, principally from the sale of Innatal, Preparent, and pathology molecular testing.
Read More on BIOR:
- Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update
- Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets
- Biora Therapeutics to sell legacy diagnostics assets, terms not disclosed
- Biora Therapeutics announces new patents for its NaviCap platform
- Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
